Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month double-blind extension study of bifeprunox versus risperidone in schizophrenia
2004-002185-38Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of bifeprunox and risperidone in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoints: Change from baseline in PANSS total score and Long-term safety and tolerability. Started Mar 2012; status: completed.
02
Drugs
bifeprunoxrisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-002185-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002185-38.